Results 51 to 60 of about 17,579 (227)

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.

PLoS Pathogens, 2013
The lipid kinase phosphatidylinositol 4-kinase III alpha (PI4KIIIα) is an essential host factor of hepatitis C virus (HCV) replication. PI4KIIIα catalyzes the synthesis of phosphatidylinositol 4-phosphate (PI4P) accumulating in HCV replicating cells due ...
Simon Reiss, Christian Harak, Inés Romero-Brey, Danijela Radujkovic, Rahel Klein, Alessia Ruggieri, Ilka Rebhan, Ralf Bartenschlager, Volker Lohmann   +8 more
doaj   +1 more source

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 [PDF]

Journal of Virology, 2011
ABSTRACT BMS-790052, targeting nonstructural protein 5A (NS5A), is the most potent hepatitis C virus (HCV) inhibitor described to date. It is highly effective against genotype 1 replicons and also displays robust genotype 1 anti-HCV activity in the clinic (M. Gao et al., Nature 465:96-100, 2010).
Robert A, Fridell, Dike, Qiu, Lourdes, Valera, Chunfu, Wang, Ronald E, Rose, Min, Gao   +5 more
openaire   +2 more sources

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Viruses, 2018
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals.
Teresa I. Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric J. Lawitz, Jens Kort, Christine Collins   +17 more
doaj   +1 more source

Phosphorylation of serine 225 in hepatitis C virus NS5A regulates protein-protein interactions. [PDF]

, 2017
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a phosphoprotein that plays key, yet poorly defined, roles in both virus genome replication and virion assembly/release.
Amako, Andreas Pichlmair, Anna Gebhardt, Berger, Chong, Christopher Bartlett, Cochrane, Cordek, Cox, Cox, De Marco, Ester, Evans, Eyre, Feuerstein, Gao, Germain, Gullberg, Gupta, Habjan, Hamamoto, Hsu, Lambacher, Lambert, Lee, Lemay, Lim, Lohmann, Love, Macdonald, Mark Harris, Masaki, Masumi, Michael S. Diamond, Miyaji-Yamaguchi, Nanda, Neuvonen, Niluka Goonawardane, Okuwaki, Paul, Pawlotsky, Pichlmair, Rehtanz, Reiss, Reiss, Romero-Brey, Ross-Thriepland, Ross-Thriepland, Schindelin, Söderberg, Takeuchi, Tellinghuisen, Tellinghuisen, Tellinghuisen, Toth, Tu, Wang, Wang, Webster, Wyles, Xu, York, Zech   +62 more
core   +1 more source

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein.

PLoS Pathogens, 2013
The nonstructural protein NS5A has emerged as a new drug target in antiviral therapies for Hepatitis C Virus (HCV) infection. NS5A is critically involved in viral RNA replication that takes place at newly formed membranes within the endoplasmic reticulum
Dorothee A Vogt, Grégory Camus, Eva Herker, Brian R Webster, Chia-Lin Tsou, Warner C Greene, Tien-Sze Benedict Yen, Melanie Ott   +7 more
doaj   +1 more source

Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection

Frontiers in Microbiology, 2021
BackgroundHepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs).
Pooneh Rahimi, Heidar Sharafi, Golnaz Bahramali, FaridehSadat SajadianFard, Nafiseh Sadat Asadi, Seyed Moayed Alavian, Vahid Iranpur Mobarakeh, Seyedeh Zahra Moravej   +7 more
doaj   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

Interaction between Nonstructural Proteins NS4B and NS5A Is Essential for Proper NS5A Localization and Hepatitis C Virus RNA Replication [PDF]

Journal of Virology, 2016
ABSTRACT The hepatitis C virus NS5A protein is tethered to cellular membranes via an amphipathic amino-terminal helix that is inserted in-plane into the outer endoplasmic reticulum (ER)-derived membrane leaflet. The charged face of the helix faces the cytoplasm and may contribute to interactions involved in replicase assembly and function ...
Avik, Biswas, Jason, Treadaway, Timothy L, Tellinghuisen   +2 more
openaire   +2 more sources

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Hepatitis C virus relies on lipoproteins for its life cycle [PDF]

, 2016
Hepatitis C virus (HCV) infects over 150 million people worldwide. In most cases, HCV infection becomes chronic causing liver disease ranging from fibrosis to cirrhosis and hepatocellular carcinoma.
Alonzi, Tonino, DI CAPRIO, Giorgia, Fimia, Gian Maria, Grassi, Germana, Ippolito, Giuseppe, Tripodi, Marco   +5 more
core   +1 more source